- Home
- NNOX vs ATXS Comparison
NNOX vs ATXS Comparison
Compare NNOX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- ATXS
- Stock Information
- Founded
- NNOX 2018
- ATXS 2008
- Country
- NNOX Israel
- ATXS United States
- Employees
- NNOX N/A
- ATXS N/A
- Industry
- NNOX Medical Electronics
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- NNOX Health Care
- ATXS Health Care
- Exchange
- NNOX Nasdaq
- ATXS Nasdaq
- Market Cap
- NNOX 426.0M
- ATXS 401.2M
- IPO Year
- NNOX 2020
- ATXS 2015
- Fundamental
- Price
- NNOX $6.30
- ATXS $6.81
- Analyst Decision
- NNOX Strong Buy
- ATXS Strong Buy
- Analyst Count
- NNOX 2
- ATXS 6
- Target Price
- NNOX $17.50
- ATXS $25.67
- AVG Volume (30 Days)
- NNOX 2.6M
- ATXS 244.9K
- Earning Date
- NNOX 03-31-2025
- ATXS 03-03-2025
- Dividend Yield
- NNOX N/A
- ATXS N/A
- EPS Growth
- NNOX N/A
- ATXS N/A
- EPS
- NNOX N/A
- ATXS N/A
- Revenue
- NNOX $10,680,000.00
- ATXS N/A
- Revenue This Year
- NNOX $22.38
- ATXS N/A
- Revenue Next Year
- NNOX $153.96
- ATXS N/A
- P/E Ratio
- NNOX N/A
- ATXS N/A
- Revenue Growth
- NNOX 10.79
- ATXS N/A
- 52 Week Low
- NNOX $5.27
- ATXS $6.64
- 52 Week High
- NNOX $12.65
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- NNOX 37.24
- ATXS 31.94
- Support Level
- NNOX $6.45
- ATXS $6.77
- Resistance Level
- NNOX $7.60
- ATXS $7.30
- Average True Range (ATR)
- NNOX 0.41
- ATXS 0.30
- MACD
- NNOX -0.11
- ATXS 0.02
- Stochastic Oscillator
- NNOX 1.29
- ATXS 14.66
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.